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Abstract
Background: The glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptors
are considered complementary therapeutic targets for type 2 diabetes. Using recombinant membrane-tethered ligand
(MTL) technology, the present study focused on defining optimized modulators of these receptors, as well as exploring how
local anchoring influences soluble peptide function.
Methodology/Principal Findings: Serial substitution of residue 7 in membrane-tethered GIP (tGIP) led to a wide range of
activities at the GIP receptor, with [G
7]tGIP showing enhanced efficacy compared to the wild type construct. In contrast,
introduction of G
7 into the related ligands, tGLP-1 and tethered exendin-4 (tEXE4), did not affect signaling at the cognate
GLP-1 receptor. Both soluble and tethered GIP and GLP-1 were selective activators of their respective receptors. Although
soluble EXE4 is highly selective for the GLP-1 receptor, unexpectedly, tethered EXE4 was found to be a potent activator of
both the GLP-1 and GIP receptors. Diverging from the pharmacological properties of soluble and tethered GIP, the newly
identified GIP-R agonists, (i.e. [G
7]tGIP and tEXE4) failed to trigger cognate receptor endocytosis. In an attempt to
recapitulate the dual agonism observed with tEXE4, we conjugated soluble EXE4 to a lipid moiety. Not only did this soluble
peptide activate both the GLP-1 and GIP receptors but, when added to receptor expressing cells, the activity persists despite
serial washes.
Conclusions: These findings suggest that conversion of a recombinant MTL to a soluble membrane anchored equivalent
offers a means to prolong ligand function, as well as to design agonists that can simultaneously act on more than one
therapeutic target.
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Introduction
Glucose-dependent insulinotropic polypeptide (GIP) and gluca-
gon-likepeptide1(GLP-1)arestructurallyrelatedincretinhormones
that are released from intestinal enteroendocrine cells in response to
food intake. Both hormones share important physiological roles,
notably in maintaining blood glucose homeostasis by potentiating
glucose-stimulated insulin secretion from pancreatic b-cells. GLP-1
and GIP also promote the expansion of pancreatic islet mass via
induction of b-cell proliferation and survival [1,2].
The GLP-1 receptor (GLP-1R) is a well-established therapeutic
target for the treatment of type 2 diabetes (T2D) [3]. In addition to
enhancing insulin secretion from pancreatic beta cells, stimulation
of this receptor also reduces blood glucose levels via effects on
extrapancreatic tissues including the gastrointestinal tract and the
brain [1]. GLP-1 triggers delayed gastric emptying which in turn
slows nutrient absorption thus attenuating the rise in blood glucose
levels. In the central nervous system, GLP-1 has been shown to
inhibit feeding behavior and to promote weight loss by stimulation
of cognate receptors, thereby further contributing to improved
glucose tolerance [1,4].
Understanding the multifunctional role of GLP-1 in modulating
glucose homeostasis led to interest in developing mimetics of this
peptide as drugs for the treatment of T2D. The lizard peptide
exendin-4 (Exenatide), a potent agonist of the GLP-1 receptor, was
the first incretin mimetic to be marketed as a treatment for T2D
[5]. A more recent addition to the therapeutic armamentarium is
liraglutide, a stable long-acting GLP-1 derivative [6]. As
complementary therapeutics, inhibitors of dipeptidyl dipeptidase-
4, the endogenous enzyme that rapidly degrades GLP-1, have also
been introduced into the clinic [5].
With respect to GIP, previous studies support that selected
mimetics exhibit potent antidiabetic actions in animal models of
T2D, resulting in improved glucose tolerance, insulin secretion
and b-cell survival [1,7]. Prior concerns regarding a partial loss of
GIP-R responsiveness in patients with T2D have been tempered
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24693by more recent studies suggesting that this defect may be reversible
once blood glucose levels are reduced (e.g., by treatment with
other drugs) [5,8]. In light of these insights, there has been a
renewed interest in developing GIP-R agonists, as well as dual
incretin receptor activators for T2D [9,10].
Both the GIP receptor (GIP-R) and the GLP-1R belong to the
glucagon subfamily of class B1 G protein-coupled receptors
(GPCRs). Although pharmacologically distinct and highly selective
for corresponding peptides, these two incretin receptors both
trigger Gs-mediated cAMP production in response to agonist
stimulation. Structure-function analyses and recent crystallograph-
ic studies support a two-domain model for incretin recognition and
receptor activation [11,12,13]. As proposed for most class B1
GPCRs, it is postulated that the C-terminal a-helical portion of
either GLP-1 or GIP initially binds the N-terminal extracellular
domain of cognate receptors; this interaction in part defines both
ligand affinity and specificity. As a second step, the N-terminal
segment of the hormone interacts with the receptor transmem-
brane domains and connecting extracellular loops. This, in turn,
leads to conformational changes in the receptor protein that
trigger intracellular signal transduction [13].
We recently reported the development of membrane-tethered
ligands (MTLs) as probes to investigate the function of class B1
GPCRs both in-vitro and in-vivo [14,15]. These recombinant
constructs are designed to encode a peptide hormone, an epitope
tag and a membrane-anchoring sequence (transmembrane
domain or glycosylphosphatidylinositol moiety), all coupled by
intervening flexible protein linkers [14,15]. As with soluble
peptides, the N-terminal amino acids of both GIP and GLP-1
MTLs include critical activity determinants; substitution within
this domain can lead to increased or decreased activity [15]. Using
the membrane-tethered ligand technology, the present study
aimed to optimize modulators of incretin receptors, as well as to
better define how local plasma membrane-anchoring may
influence ligand function. We report the discovery of both
recombinant membrane-tethered ligands and lipidated soluble
peptides that display dual incretin receptor agonism. Our results
demonstrate the utility of membrane-tethered ligands in optimiz-
ing peptide function, as well as the feasibility of mimicking the
properties of such constructs with soluble ligands that are
chemically coupled to a lipidic membrane anchor.
Results
Selected amino acid substitutions targeting position 7 of
tethered GIP enhance efficacy at the GIP-R
We have previously established that position 7 (Figure 1A)
represents an important efficacy and selectivity determinant of
membrane-tethered incretins [15]. We reported that substitution
of isoleucine 7 in tGIP with the corresponding GLP-1 amino acid,
threonine 7 (in the context of a second tGIP substitution Y
1RH
1)
was sufficient to convert tGIP to a GLP-1R agonist [15]. Notably,
position 7 among class B1 hormones has also been proposed to be
the central element of a putative helix N-capping motif important
for hormone activity and stability [16,17].
To further explore the role of this position as an activity
determinant of tGIP, this residue was serially replaced by each of
the other 19 naturally-occurring amino acids. Ligand-induced
function at the GIP-R was then assessed utilizing a CRE luciferase
reporter gene assay [15]. This screen supports the importance of
position 7 as an efficacy determinant of tGIP, and led to the
identification of constructs with markedly altered GIPR-mediated
activity, relative to unmodified tGIP (Figure 1B). Substitution with
the negatively charged amino acids aspartic acid (D) and glutamic
acid (E) markedly impaired activity, while introduction of the
positively charged lysine (K) and arginine (R) residues led to a
gain-of-function. Interestingly, substitution of residue 7 with
glycine (G), which has a minimal side chain, also significantly
increased ligand function. In contrast, non-polar residues includ-
ing alanine (A), leucine (L), methionine (M), when introduced at
position 7, had no apparent impact on ligand activity.
To better understand the mechanism underlying increased
tethered ligand function, the K and G substituted derivatives were
selected for further analysis. Enhanced function of these tethered
ligands was confirmed over a wide range of cDNA concentrations
(Figure 1C). Both of these tethered gain-of function analogs were
selective for the GIP-R, displaying no activity at the GLP-1R (data
not shown; Table 1). To evaluate whether the increase in activity
of [G
7]tGIP and [K
7]tGIP was the result of higher tethered ligand
expression, surface levels of corresponding constructs were
quantified (Figure 1D). ELISA data exclude that enhanced activity
is the consequence of increased tethered ligand expression.
Impact of the G
7 and K
7 substitutions on the function of
the related tGLP-1 and tEXE4 constructs
The N-terminus of GIP in the vicinity of residue 7 is highly
homologous to that of the GLP-1R agonists GLP-1 and EXE4
(Figure 1A). We therefore investigated whether G
7 and K
7
substitutions would also enhance the function of the latter peptides
on their target receptor. As demonstrated previously, wild-type
forms of tethered GLP-1 and EXE4 were potent activators of the
GLP-1R [15]. Substitution of position 7 with glycine ([G
7]tGLP-1
and [G
7]tEXE4) resulted in activity comparable to the correspond-
ing unmodified ligands when assessed at the GLP-1R. In contrast,
introductionoftheK
7substitutionintGLP-1andtEXE4completely
abrogated the ability of both ligands to trigger GLP-1R mediated
signaling (Figure 2A–B). As observed with tGIP, position 7 in tGLP-
1 and tEXE4 was thus critical for efficacy yet in the latter peptides
neither substitution enhanced activity at the cognate GLP-1R.
We previously demonstrated that the residue in position 7 of related
incretin ligands can determine the selectivity of tethered ligands for
the GLP-1R versus the GIP-R. On this basis, we next evaluated the
function of tGLP-1 and tEXE4-based constructs at the GIP-R. Wild-
type as well as both the G
7 and K
7 tGLP-1 analogs were inactive at
the GIP-R (Figure 2C). Unexpectedly, however, the wild-type EXE4
membrane-tethered construct was a potent GIP-R activator, in fact
triggering activity levels higher than tGIP itself. Both [G
7]tEXE4 and
[K
7]tEXE4 analogs displayed reduced GIP-R mediated signaling,
relative to unmodified tGIP and tEXE4 (Figure 2D).
Taken together, our studies have identified two tethered ligands,
[G
7]tGIP and tEXE4, which each exhibit GIP-R mediated
signaling higher than that of tGIP. Notably, tEXE4 was a dual
agonist with full activity at both the GLP-1R and GIP-R. A
summary of the activity and selectivity of wild-type, as well as G
7
or K
7 substituted tethered incretin constructs is shown in Table 1.
Soluble [G
7]GIP and EXE4 are low potency GIP-R agonists
To better define the impact of membrane-tethering on ligand
function, comparative studies were done to examine the effects of
soluble EXE4, GLP-1, GIP and [G
7]GIP at the GIP-R and GLP-
1R. Soluble EXE4 and GLP-1 were full agonists at the GLP-1R,
whereas GIP and [G
7]GIP had minimal if any activity (Figure 3A).
On cells expressing the GIP-R, [G
7]GIP and EXE4 were agonists
with potencies ,100-fold and ,50,000 fold lower than unmodified
GIP, respectively (Figure 3B). GLP-1 was an even lower potency
agonist. These observations contrast with the gain-of-function
observed at the GIP-R when tethered constructs, [G
7]tGIP and
tEXE4, were compared to tGIP wild-type (Figure 1C and 2D).
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24693Figure 1. Functional consequences of amino acid substitutions targeting position 7 in tethered GIP. HEK 293 cells were transiently
transfected with the GIP-R cDNA and a tethered GIP construct, together with a CRE6X-LUC reporter gene construct. Twenty four hours post-
transfection, luciferase activity was quantified as described in Methods. (A) Sequence comparison of human GIP and GLP-1 hormones, and of EXE4.
Position 1 represents the N-terminal residue of the peptides. Within the first 9 amino acids, GIP and GLP-1 differ only at positions 1 and 7 (boxes). (B)
Serial substitution of isoleucine 7 in tGIP by each of the other 19 amino acids leads to a wide range of tethered ligand-induced activities at the GIP-R.
The constructs showing activities similar to wild-type are shown in light gray. The constructs displaying significantly reduced or increased activity
versus wild-type tGIP are shown in white and dark gray, respectively. (C) Assessment of tethered ligand activity with increasing amounts of
transfected cDNA, confirm the enhanced activity of the [G
7] tGIP and [K
7] tGIP derivatives (arrow), relative to wild-type tGIP. (D) Comparable cell
surface expression of tGIP, [G
7] tGIP and [K
7] tGIP, as assessed by ELISA following transfection of increasing amounts of corresponding cDNAs. All
activity or expression data were normalized relative to the wild-type tethered GIP values. Data represent the mean 6 SEM from at least 4
independent experiments, each performed at least in quadruplicate. The activity of mutant versus wild-type tGIP were compared by analysis of
variance followed by Dunnett’s post-test; significance, *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0024693.g001
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the GIP-R
To investigate the mechanism underlying the enhanced
function of [G
7]tGIP and tEXE4 (vs tGIP), we examined how
tethered ligands modulate GIP-R surface expression using a
previously described ELISA assay [18]. The effects of soluble
ligands were assessed in parallel.
As anticipated based on the literature [19], surface expression of
the HA-tagged GIP-R was markedly reduced after prolonged
incubation with increasing doses of soluble GIP (Figure 4A). In
contrast, high concentrations of the soluble agonists [G
7]GIP or
EXE4 failed to down-regulate receptor levels. In fact, overnight
incubation with EXE4 significantly increased receptor levels.
GLP-1, which is inactive at the GIP-R, also showed no effect on
GIP-R membrane expression levels (negative control).
As observed with soluble GIP, expression of the wild-type
tethered GIP construct significantly decreased GIP-R surface levels
(Figure 4B). In contrast, despite being highly active in triggering
signaling, [G
7]tGIP had no significant effect on GIP-R expression
(Figure 4B). As observed with the corresponding soluble ligand,
tEXE4 significantly increased GIP-R levels. The inactive tGLP-1
construct showed no effect on GIP-R membrane expression levels.
We further explored how tethered ligands influence putative
GIP-induced endocytosis (Figure 4C). Increased expression of
tGIP, [G
7]tGIP and tEXE4 each significantly attenuated receptor
endocytosis induced by soluble GIP (100 nM, 18 h). In contrast,
tGLP-1 had no impact on GIP-R endocytosis (negative control).
Taken together, these data support that selected agonists (either
soluble or tethered) can activate the GIP-R without triggering
endocytosis.
Table 1. Relative activity of wild-type and G
7/K
7 tethered
incretin derivatives at the GIP and GLP-1 receptors.
GIP-R GLP-1R
tGIP ++ 2
[G
7]tGIP +++ 2
[K
7]tGIP +++ 2
tGLP-1 2 ++
[G
7]tGLP-1 2 ++
[K
7]tGLP-1 22
tEXE4 +++ ++
[G
7]tEXE4 ++ +
[K
7]tEXE4 + 2
Notably, tethered EXE4 is a potent activator of both receptors.
doi:10.1371/journal.pone.0024693.t001
Figure 2. Activity and selectivity of wild-type and G
7/K
7 derivatives of tGLP-1 and tEXE4. Activity of tethered GLP-1 and tethered EXE4
constructs at both the GLP-1R (A and B) and the GIP-R (C and D) are compared. HEK 293 cells were transiently transfected with cDNAs encoding the
GLP-1R or GIP-R, a tethered ligand, and a CRE6X-LUC reporter gene construct. Twenty four hours post-transfection, ligand-induced activity was
quantified as described in Methods. All activity data were normalized relative to the corresponding wild-type tethered GIP, GLP-1 or EXE4 construct,
as indicated. Unexpectedly, a tethered version of wild-type EXE4 displayed high activity not only at the GLP-1R, but also at the GIP-R (arrow). Data
represent the mean 6 SEM from at least 4 independent experiments, each performed at least in quadruplicate.
doi:10.1371/journal.pone.0024693.g002
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distribution of the GIP-R
The impact of soluble GIP versus selected tethered activators on
the subcellular localization of the GIP-R was further characterized
by confocal imaging. For this purpose, we generated a fusion protein
which includes the GIPR tagged with a monomeric cherry
fluorescent protein (CHE) on the C-terminus (GIPR-CHE).
Fluorescent tethered ligands were also generated with the green
fluorescent protein (GFP) at the C-terminal end of the constructs
(Figure S1A–B). Receptor and tethered ligand fusion proteins each
showed activity similar to their corresponding untaggedcounterparts
when assessed using LUC-reporter gene assay (data not shown).
Under basal conditions, GIPR-CHE expressing cells showed
plasma membrane-labeling, as well as occasional punctate
intracellular staining. Prolonged treatment with soluble GIP
triggered massive GIPR-CHE endocytosis, characterized by
fluorescence accumulation in intracellular compartments
(Figure 5A). The subcellular localization of internalized GIP-Rs
was investigated using a Rab7-GFP marker which labels
intracellular endosomal compartments [20] (Figure S2). Support-
ing that chronic treatment with GIP leads to GIPR-CHE
translocation to late endosomes, both Rab7-GFP and the receptor
colocalized intracellularly following agonist treatment.
Consistent with our ELISA results, the cell surface distribution
of GIPR-CHE was not altered following treatment with high doses
of either soluble [G
7]GIP or EXE4 (Figure 5A) . Further
supporting that corresponding [G
7]tGIP-GFP and tEXE4-GFP
membrane-tethered ligands do not induce receptor endocytosis,
both constructs were colocalized with the GIPR-CHE at the
plasma membrane (Figure 5B). Furthermore, tEXE4-GFP blocked
receptor endocytosis induced by soluble GIP, whereas tGLP1-GFP
had no effect (Figure 6A).
To visually confirm GIPR-mediated signaling in cells expressing
GFP-tagged tethered activators, a CRE6x-CHE reporter gene was
generated (Material and methods, Figure S1). Consistent with
luciferase assays, both [G
7]tGIP-GFP and tEXE4-GFP triggered
GIP-R dependent signaling (intracellular accumulation of CHE)
(Figure 6B). In contrast, the surface-expressed tGLP1-GFP
construct (negative control) failed to activate the GIP-R. These
data further support that selected tethered agonists may trigger
signaling without inducing receptor internalization.
Lipidated peptides can recapitulate selected properties
of recombinant tethered ligands
Based on the enhanced potency of EXE4 at the GIP-R
following membrane-tethering (Figure 2D), we postulated that
similar effects might be reproduced using a soluble membrane-
anchored version of this peptide. To explore this possibility, an
EXE4 peptide linked to a GM1 ganglioside (acting as the lipidic
membrane-anchoring moiety) was characterized (EXE4-GM;
Figure 7A). Supporting that GM1 could act as an effective
membrane anchor, previous work demonstrated rapid plasma
membrane insertion of fluorescent gangliosides when added to
cultured cells [21].
As predicted by recombinant membrane-tethered ligand, the
signaling potency of the EXE4-GM compound was enhanced by
,50 fold relative to the EXE4 peptide when assessed at the GIP-R
(Figure 7B; pEC50=7.2860.25 versus 8.9460.05 for EXE4 and
EXE4-GM, respectively; mean6 SEM). When measured at its
primary target, the GLP-1R, EXE4-GM remained a high potency
agonist (EC50=48 pM, pEC50=10.2560.10), whereas this con-
struct lacked activity in cells transfected with the empty vector
pcDNA1 in place of receptor cDNA (data not shown).
To further test the hypothesis that increased potency of EXE4-
GM at the GIP-R is attributable to local membrane-anchoring, we
analyzed the persistence of agonist-induced signaling with serial
washes [22]. Whereas potency and efficacy of GIP and unmodified
EXE4 were markedly decreased following washes, the activity of
EXE4-GM was minimally affected (Figure 7C–E). This observa-
tion supports that lipidation of EXE4 enhances binding of the
ligand to the cell surface, reminiscent of a recombinant MTL.
Discussion
We have performed a comparative analysis of soluble versus
tethered peptides targeting the GIP-R and GLP-1R that has
begun to reveal how membrane-anchoring in combination with
single amino acid substitutions alters the actions of corresponding
Figure 3. Signaling potency of soluble incretin peptides at the
GLP-1 and GIP receptors. Soluble ligand concentration-response
curves for GLP-1, EXE4, GIP and [G
7] tGIP were assessed on cells
expressing the GLP-1R (A) or the GIP-R (B). HEK293 cells were transiently
transfected with cDNAs encoding the indicated receptor and a CRE6X-
LUC reporter gene construct. Twenty four hours post-transfection, cells
were stimulated for 6 hours with soluble peptides; ligand-induced
activity was then quantified. All activity data were normalized relative to
soluble EXE4 (A) or GIP (B). Both soluble GLP-1 and EXE4 were highly
potent agonists at the GLP-1R, and low potency agonists at the GIP-R.
GIP and [G
7] tGIP only showed activity at the GIP-R. Data represent the
mean 6 SEM from at least 4 independent experiments, each performed
at least in quadruplicate.
doi:10.1371/journal.pone.0024693.g003
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first generation membrane-anchored, peptide-lipid conjugate
which activates both incretin receptors.
Our studies initially focused on the role of residue 7 as a critical
determinant of agonist activity at the GIP-R. This position was
selected for exploration based on two intersecting lines of
investigation. In a prior study, we had demonstrated that
interchange of GIP and GLP-1 residues in this position
contributed to the activity of both tethered ligands at their
cognate receptors [15]. In addition, position 7 is part of a highly
conserved helix capping structure common to class B1 hormones
[16,17]. The corresponding motif is predicted to favor a-helix
Figure 4. Comparison of soluble versus tethered ligand-induced modulation of GIP-R surface expression. The impact of soluble
peptide (A), tethered ligands (B) and the interaction between soluble and tethered ligands on HA-GIPR surface expression (C) was measured by ELISA.
HEK 293 cells were transfected with a plasmid encoding the HA-tagged GIP-R, with or without increasing amounts of a tethered ligand cDNA. Twenty
four hours after transfection, soluble ligands were added in selected wells, as indicated. In each experiment, receptor expression was evaluated
48 hours after transfection. Soluble and tethered GIP were the only ligands able to down-modulate HA-GIPR expression (A, B). Tethered GIP, [G
7] tGIP
and tEXE4 interfered with soluble GIP-induced endocytosis (C). Data represent the mean 6 SEM from at least 4 independent experiments, each
performed in 12 replicates. The expression of HA-GIPR in the absence vs presence of soluble or tethered ligand were compared by analysis of
variance followed by Dunnett’s post-test; significance, *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0024693.g004
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isoleucine 7 in tGIP led to constructs with variable levels of activity
at the GIP-R. Detailed follow-up analysis revealed that both the
G
7 and K
7 substitutions led to enhanced activity which was not
attributable to an increase in construct expression and was thus of
particular interest.
Supporting the role of position 7 as an efficacy/selectivity
determinant of class B1 ligands at their cognate receptor,
introduction of K
7 in the related tGLP-1 and tEXE4 peptides
markedly reduced activity at the GLP-1R. In contrast, the G
7
substitution was well-tolerated when introduced into tGLP-1 and
tEXE4. Extending this analysis to other closely-related class B1
peptides, introduction of G
7 into tethered forms of the vasoactive
intestinal polypeptide (VIP) and the pituitary adenylate cyclase-
activating peptide (PACAP27), markedly potentiated ligand
activity at the VPAC-1R (Figure S3). Previous structure-function
studies on soluble PACAP complement our findings and support a
role of this capping structure for both peptide activity and stability
[24,25]. A recent study further reported that introduction of A
7 in
PACAP38 leads to a superagonist peptide [26]. Taken together,
our results and the literature suggest the importance of position 7
as an efficacy/selectivity determinant in both soluble and tethered
forms of hormones acting on class B1 GPCRs.
In the current investigation, we have also shown that membrane-
tethered EXE4 displays an unexpected high activity level at the
GIP-R, in fact exceeding that of tethered GIP. Earlier studies have
primarily focused on EXE4 as a GLP-1R agonist [1]. It is of note
that membrane-tethering failed to potentiate the activity of GLP-1,
despite the fact that this low potency GIP-R agonist shares a similar
N-terminal sequence with EXE4. Moreover, rendering the N-
terminal tGLP-1 domain identical to tEXE4 using a G
2 substitution
did not further increase GIP-R-dependent activity (data not shown).
Figure 5. Analysis of soluble versus tethered ligand-induced GIP-R endocytosis using fluorescently-tagged constructs. The impact of
selected soluble peptides (A) and tethered ligands (B) on the subcellular distribution of GIPR-CHE was studied using confocal microscopy. HEK 293
cells were transiently transfected with a plasmid encoding the GIPR-CHE, with or without cDNA encoding a GFP-tagged tethered ligand. Twenty-four
hours later, the cells were treated for 18 hours with a soluble peptide or the corresponding vehicle, as indicated. The subcellular distribution of
receptor was then visualized. Whereas soluble GIP triggered massive endocytosis, other soluble and tethered ligands had no apparent effect.
doi:10.1371/journal.pone.0024693.g005
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enhanced ability to effectively modulate the GIP-R as a tethered
ligand. Among other explanations, this difference could in part stem
from the fact that GLP-1 has a less stable secondary helical
structure, when compared with EXE4 [12].
To further explore how tethering influences ligand activity/
potency, we compared the properties of soluble versus tethered
forms of GIP, [G
7]GIP and EXE4. In contrast to the enhanced
function of tethered EXE4 (relative to tethered GIP), the soluble
EXE4 peptide exhibits a ,5,000 fold lower potency than soluble
GIP. Similarly, a [G
7]GIP derivative had lower potency than GIP
when assessed as a soluble peptide. Such differences between the
relative activities of soluble ligands and tethered constructs support
our previous suggestion that membrane-anchoring creates a high
local concentration of ligand in the receptor vicinity, and thus
potentiates the ability of selected low potency agonists to activate a
receptor [15].
To better understand the enhanced activity of [G
7]tGIP and
tEXE4, we studied the ability of these ligands to modulate GIP-R
cell surface expression levels. Consistent with a prior report [27],
our ELISA and microscopy analyses demonstrate that prolonged
treatment with soluble GIP triggers receptor internalization and
trafficking to the endosomal compartment. Similarly, expression of
the tethered version of GIP also lowers surface expression of the
GIP-R. In contrast, both [G
7]tGIP and tEXE4, while signaling to
a level exceeding that of tGIP, do not decrease GIP-R surface
expression after long-term stimulation. Furthermore, these con-
structs block receptor endocytosis induced by soluble GIP.
Reminiscent of the differential effects on signaling vs internaliza-
tion observed with membrane-tethered ligands, a recent study
reported biased activators of opioid receptors that trigger
efficacious G-protein dependent signaling, while simultaneously
acting as antagonists of receptor internalization and down-
regulation [28]. It is possible that the lack of ligand-induced
receptor endocytosis contributes to the increased efficacy of
[G
7]tGIP and tEXE4. The proposed link between reduced
internalization and enhanced signaling is supported by additional
studies on both class A and B GPCRs including the GLP-1R and
GIP-R. These experiments showed that interfering with the
process of receptor internalization/desensitization can amplify the
level of ligand-induced G-protein mediated signaling
[19,29,30,31].
It is of note that long-term incubation with soluble or tethered
EXE4 slightly up-regulated GIP-R surface levels. As observed with
Figure 6. Impact of tethered ligand expression on soluble GIP-induced endocytosis of the GIP-R. (A) Expression of tEXE4-GFP blocked
soluble GIP induced-endocytosis of GIPR-CHE. Cells were transfected with plasmids encoding GIPR-CHE and tEXE4-GFP or tGLP1-GFP. Twenty-four
hours later, the cells were treated for 18 h with media containing 100 nM of soluble GIP, followed by confocal microscopy imaging. (B) Both [G
7]tGIP-
GFP and tEXE4-GFP induced high receptor-dependent signaling, relative to the inactive tGLP1-GFP construct. HEK293 cells were transfected with
plasmids encoding the untagged GIP-R, a GFP-tagged tethered ligand, together with a CRE6x-CHE reporter construct, as described in Methods.
Intracellular CHE accumulation was visualized 48 hours after transfection.
doi:10.1371/journal.pone.0024693.g006
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inhibition of constitutive receptor endocytosis and recycling [32].
Alternatively, it is possible that recombinant membrane-tethered
ligands interact with newly synthesized GIP-Rs and favor the
processing of these receptors to the cell surface [33].
One of the challenges of membrane-tethered ligands if they are
to be used clinically is delivery. Recombinant constructs are
amenable to gene therapy; however this is accompanied by
additional risks [34]. To circumvent this concern, we now report
that selected properties of recombinant tethered ligands can be
Figure 7. Signaling properties of a ganglioside-EXE4 conjugate. (A) Cartoon of an EXE4-ganglioside conjugate (EXE4-GM) interacting with
the cellular membrane. (B) Potency of EXE4-GM compared with that of soluble EXE4 and GIP at the GIP-R. (C–E) Unmodified GIP (C) and EXE4 (D)
showed reduced function with serial washes, whereas the activity of EXE4-GM (E) persisted. HEK293 cells were transiently transfected with a cDNA
encoding the GIP-R, together with a CRE6X-LUC reporter gene construct. Twenty four hours post-transfection, cells were stimulated for 15 minutes
with increasing concentrations of the indicated ligands. As indicated, selected wells were then washed three times with serum-free media, and plates
were further incubated for an additional 4 hour period. Luciferase activity was subsequently measured as described in Methods. Activity data were
normalized relative to the soluble GIP-induced maximum. Data represent the mean 6 SEM from at least 4 independent experiments, each performed
at least in quadruplicate.
doi:10.1371/journal.pone.0024693.g007
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Notably, an EXE4 derivative fused with a ganglioside (acting as a
membrane anchor) exhibited significantly higher potency than the
free EXE4 peptide when assessed at the GIP-R. Previous work
demonstrated that plasma membrane incorporation of exogenous-
ly added gangliosides is influenced by a number of parameters
including the temperature, incubation time, as well as the presence
of lipid carriers [21]. Optimization of delivery conditions and
membrane-anchored ligand structure (e.g. ligand composition,
length of the linker between the peptide and lipid group, nature of
the membrane-anchor) may further enhance the potency of
lipidated EXE4 derivatives.
Increasing evidence supports that the potency and duration of
drug action are influenced by the extent of target association [35].
This concept has been primarily ascribed to small lipophilic
molecules, for which incorporation in the lipid bilayer is postulated
to affect the residency time near the receptor. A well-known
example is the long-acting b2 adrenergic agonist salmeterol, which
has a high tendency to partition into cell membranes due to an
extended lipophilic side chain [36]. Interestingly, as a mechanism
underlying its prolonged in vivo effects, studies have proposed that
salmeterol may be less prone to induce b2 adrenergic receptor
endocytosis, relative to full agonists [37]. Importantly, sustained
receptor activation by salmeterol survives extensive wash proce-
dures [22], a result that was confirmed in our hands (data not
shown). Our observation that receptor-mediated signaling induced
by the EXE4-GM derivative persists under similar wash conditions
is consistent with membrane-insertion of the lipidated peptide.
Our data further support (as documented for selected small
molecules), that hindering diffusion away from target receptors
may offer a strategy to potentiate the actions of peptidic ligands.
In the design of effective incretin mimetics for type 2 diabetes,
recent efforts have focused on improving their pharmacokinetic
properties, including plasma half-life [1]. Notably, acylated
derivatives of both GLP-1 (e.g. Liraglutide) and GIP are being
developed as long-acting antidiabetic drugs [6,9]. Structurally, the
design of such analogs markedly differs from EXE4-GM in that
fatty-acids are covalently linked to lysine residues within the C-
terminal portion of the hormones [9,38]. Interestingly, despite the
addition of large substituents within the domain proposed to bind
the receptor [11,12], many of these lipidated incretins (when
pharmacologically assessed in vitro) have potencies similar to or
even higher than those of the corresponding unmodified hormones
[9,39]. Although fatty-acid conjugation is known to prolong
circulating peptide half-life by facilitating binding to plasma
proteins, previous work also suggests that lipid groups increase
affinity for cellular membranes [40]. Extending from our results
with EXE4-GM, it is possible that interaction with the plasma
membrane also impacts the properties of some recently developed
acylated incretin analogs.
Therapeutics mimicking the activities of multiple gut hormones
represent an emerging theme in the treatment of diabetes and
obesity [4]. The promise of this approach is highlighted by recent
reports of a dual peptide agonist, acting at both the GLP-1 and
glucagon receptors, which reverses obesity in rodents [41,42].
Although dual-action activators of the GLP-1R and GIP-R have
yet to be reported, recent literature supports the potential of such
molecules for the treatment of T2D [4,10,43]. Our current data
suggest that a membrane-anchored form of exendin-4 may
represent a promising lead molecule which with further optimi-
zation may result in a potent GIP-R and GLP-1R dual-agonist.
Such ligands could theoretically combine the beneficial effects of
GLP-1 on gastric emptying, appetite control and body weight,
with an enhanced ability to improve b-cell function and mass via
both receptors [10]. It is of note that the diminished insulinotropic
actions of GIP observed in T2D patients are recovered with
normalization of blood glucose levels [5,8]. Consequently, GLP-
1R mediated improvement of hyperglycaemia could gradually
enhance the antidiabetic actions of a dual agonist simultaneously
acting via GIP-Rs.
In conclusion, this study reports the identification and molecular
characterization of novel membrane-anchored ligands displaying
GIPR-selective, as well as dual incretin receptor agonism. This
work further suggests that the activity of selected efficacious
membrane-tethered peptides can be recapitulated by designer
lipid-peptide conjugates. These optimized lipidated ligands may
also provide a means to produce sustained receptor-mediated
activity in targeted tissues. Considering that our recombinant
approach was previously shown to accommodate the vast majority
of class B1 GPCR hormones [14,15], it may be anticipated that
additional peptides belonging to this family will show altered and
potentially therapeutically useful pharmacologic properties when
conjugated to gangliosides or other membrane-anchors.
Materials and Methods
Generation of Tethered Ligand, GPCR and Reporter Gene
Constructs
The pcDNA1.1 plasmids encoding membrane-tethered versions
of GIP, GLP-1 and EXE4, as well as the wild-type GIP-R and
GLP-1R, have been described previously [15,18,44]. Amino acid
substitutions were introduced into selected tethered ligands using
oligonucleotide-directed site-specific mutagenesis, as previously
reported [45]. Tethered ligand constructs with enhanced green
fluorescent protein (GFP) at the C-terminus were generated using
a stepwise approach. Using site-directed mutagenesis, stop codons
were substituted by a sequence encoding a linker (five glycine-
serine (GS) repeats) and a XhoI restriction site. The GFP coding
sequence (pEGFP-N3; Clontech Laboratories Inc. Palo Alto, CA)
was amplified by polymerase chain reaction (PCR) using sense (59-
ACCGCTCGAGATGGTGAGCAAGGGCGAGGAG-39) and
antisense (59-GATCTCTAGATTACTTGTACAGCTCGTC-
CATGC-39) primers, which include additional XhoI and XbaI
sites (underlined), to enable directional cloning of the GFP
fragment. The cDNAs encoding the modified tethered ligand
and the GFP PCR product were then digested (XhoI/XbaI) and
ligated. The composition of the resulting GFP-labeled tethered
ligand constructs is shown in Figure S1A. The cDNAs encoding
the GIP-R with monomeric cherry fluorescent protein (CHE) at
the C-terminus were generated using a parallel strategy. Briefly,
the stop codon in the receptor cDNA was replaced by a XhoI site
using site-specific mutagenesis. The CHE coding sequence was
amplified by PCR (using the same primers specified above),
digested with XhoI and XbaI, and then ligated at the 39 end of the
receptor-coding sequence. The reporter plasmid including CHE
under the control of a multimerized cAMP-responsive element
(CRE6x-CHE) was produced by modification of a previously
described CRE6x-luciferase (LUC) construct [15]. Using this
template, the LUC coding sequence was substituted by that of
CHE. The nucleotide sequence of all tethered ligands, receptor
and reporter constructs was confirmed by automated DNA
sequencing.
Synthesis of [G
7]GIP and EXE4-GM derivatives
The peptides GIP and [G
7]GIP were synthesized at the Tufts
University Core Facility using solid phase peptide synthesis on ABI
431 instruments employing Fmoc chemistry. Peptides were
purified by reverse HPLC (C18 columns). Synthesis of the
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(Gardner, MA). All other ligands used in the present study were
from American Peptide Company Inc. (Sunnyvale, CA).
Cell Culture
Human embryonic kidney (HEK) 293 cells [15] were grown in
Dulbecco’s modified Eagle’s medium (Gibco, Carlsbad, CA)
supplemented with 10% fetal bovine serum, 100 U/ml penicillin
G and 100 mg/ml streptomycin. The cells were maintained at
37uC in a humidified environment containing 5% CO2.
Luciferase Reporter Gene Assay
Receptor-mediated signaling was assessed using a previously
described luciferase assay [15,18]. In brief, HEK293 cells were
plated at a density of 3000–6000 cells per well into clear-bottom,
white 96-well plates and grown for 1–2 days to ,80% confluency.
Cells were then transiently transfected using Lipofectamine
R
reagent (Invitrogen, Carlsbad, CA) with cDNAs encoding (i) a
GPCR (or the empty expression vector), (ii) a tethered ligand
(where applicable), (iii) the CRE6X-LUC reporter gene and (iv) b-
galactosidase (as a control for transfection efficiency). For
experiments investigating the agonist function of soluble peptides,
tethered ligand cDNA was not included in the transfection
reaction. Twenty four hours after transfection, cells were
incubated with or without selected soluble peptide in serum-free
medium for 6 hours. Following ligand stimulation, the medium
was gently aspirated, the cells were lysed and luciferase activity was
quantified using a TopCount NTX after addition of Steadylite
R
reagent (PerkinElmer, Boston, MA). A b-galactosidase assay was
then performed after adding the enzyme substrate 2-Nitrophenyl
b-D-galactopyranoside, and incubating at 37uC for 30–60 min-
utes. Substrate cleavage (an index of b-galactosidase expression
was quantified by measurement of optical density at 420 nm using
a SpectraMax
R microplate reader (Molecular Devices, Sunnyvale,
CA). Corresponding values were used to normalize the luciferase
data for transfection efficiency.
Washout Experiments
The persistence of agonist activity was assessed using a
luciferase-based assay adapted from a previously reported
procedure [22]. Briefly, HEK293 cells were plated and transfected
as described above, with the exception that 96-well plates were
pretreated with poly-L-lysine to maximize cell adhesion. Twenty-
four hours after transfection, cells were treated with increasing
concentrations of an agonist and further incubated for 15 minutes
at 37uC. Selected wells were then washed three times with serum-
free medium and plates were incubated for an additional 4 hour
period. Receptor-mediated activity was quantified as described.
Assessment of Tethered Ligand and GPCR Expression
Using ELISA
The surface expression levels of myc-tagged tethered ligands or
HA-tagged GIP-Rs were assessed using a previously-established
procedure [15,18]. HEK293 cells grown in 96-well clear Primaria
plates (BD Biosciences, Bedford, MA) were transiently transfected
with either pcDNA1.1 or a cDNA encoding the relevant epitope-
tagged proteins (tethered ligand and/or GIP-R). In selected
experiments, 24 hours post-transfection, cells were treated with
soluble ligands and incubated for an additional 24 hour period.
Forty-eight hours post-transfection, the cells were washed once
with phosphate buffered saline (PBS) (pH 7.4) and fixed with 4%
paraformaldehyde in PBS for 10 min at room temperature. After
washing with 100 mM glycine in PBS, the cells were incubated
for 30 min in blocking solution (PBS containing 20% bovine
serum). To detect epitope on the recombinant proteins (myc-
tagged MTLs or HA-GIPR), a horseradish peroxidase (HRP)-
conjugated antibody directed against the myc-tag (polyclonal,
1:1500 in blocking buffer, cat. #ab19312, Abcam Inc) or HA-tag
(monoclonal, 1:500 in blocking buffer, clone 3F10, Roche Inc.)
was then added to the cells. After 1 hour, the cells were washed
five times with PBS. Fifty ml per well of a solution containing the
peroxidase substrate BM-blue (3.39-5, 59-tetramethylbenzidine,
Roche Applied Science, Indianapolis, IN) was then added. After
incubation for 30 min at room temperature, conversion of this
substrate by antibody-linked HRP was terminated by adding 2 M
sulfuric acid (50 ml per well). Light absorbance at 450 nm was
quantified as a measure of protein expression) using a
SpectraMax
R microplate reader.
Confocal Microscopy
HEK293 cells were plated at a density of 150,000 cells per dish
onto poly-L-lysine coated 35 mm glass bottom dishes (MatTek
Corporation, Ashland, MA) and grown for 1 day to ,60–80%
confluency. Cells were then transfected with cDNA encoding
GIPR-CHE and a GFP-tagged tethered ligand construct. In some
experiments, soluble peptides were added 24 hours after transfec-
tion and cells were incubated at 37uC for an additional 18–
24 hours before imaging. Forty eight hours following transfection,
the cells were washed once with PBS and fixed with 4%
paraformaldehyde in PBS for 10 minutes. After washing with
100 mM glycine in PBS, cells were washed twice with PBS and
subsequently kept in the same solution. Images were obtained
using confocal miscroscopy (Leica TCS SP2 instrument).
Data Analysis
Sigmoidal curve fitting of ligand concentration-response curves
was done using GraphPad (GraphPad Prism software version 5.0,
San Diego, CA). The same software package was used for
calculating the half maximal effective concentrations (EC50
values), an index of ligand potency.
Supporting Information
Figure S1 Cartoon illustrating the use of fluorescent
proteins to detect MTLs, GPCRs and reporter gene
activation. (A) Protein domains encoded by the GFP-tagged
tethered ligand constructs. Amino acids are indicated by the
single-letter code. (B) A schematic representation of a GFP-labeled
tethered ligand interacting with a CHE-tagged GPCR. (C)
Receptor-mediated signaling induced by a GFP-tagged tethered
ligand leads to intracellular accumulation of CHE following
activation of the CRE6X-CHE reporter gene.
(TIFF)
Figure S2 Agonist-induced translocation of the GIP-R to
endosomal compartments. The impact of soluble GIP on the
subcellular distribution of GIPR-CHE was explored using confocal
microscopy. HEK293 cells were transiently transfected with a
plasmid encoding the GIPR-CHE and a GFP-tagged version of
the the endosomal marker Rab7. Twenty-four hours later, the cells
were treated for 18 h with media containing 100 nM of GIP or the
corresponding vehicle. The subcellular distribution of receptor was
then visualized. Soluble GIP triggered internalization of the
GIPR-CHE to a vesicular endosomal compartment containing the
Rab7-GFP marker, as suggested by the co-localization of the
corresponding fluorescent tags.
(TIFF)
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7 in membrane-tethered
forms of VIP or PACAP27 markedly enhances receptor-
mediated signaling. Introduction of the G
7 substitution into
tVIP (A) or tPACAP27 (B) markedly enhanced the ability of both
ligands to trigger endogenous VPAC-1R -mediated signaling.
HEK293 cells were transiently transfected with cDNAs encoding a
tethered ligand and a CRE6X-LUC reporter gene construct.
Twenty four hours post-transfection, ligand-induced activity was
quantified. All activity data were normalized relative to the
corresponding wild-type tethered VIP or PACAP construct, as
indicated. (C) Sequence comparison of human GIP, VIP,
PACAP27, GLP-1 and EXE4 hormones. Position 1 represents
the N-terminal residue of the peptides. A highly conserved helix-
capping motif among class B1 hormones includes residue 7 (red),
as well as positions 6 and 10 (blue) (Neumann et al. 2008; Parthier
et al. 2009). This sequence motif is identical between GIP, VIP
and PACAP27. Data represent the mean 6 SEM from at least 3
independent experiments, each performed in quadruplicate.
(TIFF)
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